NCT00417976View on ClinicalTrials.gov

Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

March 31, 2010

Study Completion Date

February 28, 2011

Conditions
Pancreatic Cancer
Interventions
DRUG

Gemcitabine

1000 mg/m2 over 100 minutes every 2 weeks.

DRUG

Bevacizumab

10 mg/kg every 2 weeks.

DRUG

Infusional 5-Fluorouracil

2400 mg/m2 over 48 hours every 2 weeks.

Trial Locations (2)

43210

The Ohio State University James Cancer Hospital, Columbus

48109

The University of Michigan, Ann Arbor

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Tony Bekaii-Saab

OTHER